Modifications of gut microbiota are associated with the severity of IgA nephropathy in the Chinese population

Zhong, Zhengxia; Tan, Jindong; Li, Tan; Tang, Yi; Qiu, ZhiCheng; Pei, Gaiqin; Qin, Wei

doi:10.1016/j.intimp.2020.107085

Cited by 39 publications

(77 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 25 studies included 1436 patients with CKD and 918 healthy controls (Table 1). Nine studies focused on ESRD; 12 focused on CKD ranging in severity from stage 1 to 5; and four focused on two specific pathological types of CKD: IgA nephropathy (IgAN) [17][18][19] and DN [20]. Seventeen studies were carried out in China, three in the US, two in Italy, and one in Austria, Brazil, and Netherlands.…”

Section: Study Selection Characteristics and Qualitymentioning

confidence: 99%

“…Six (6/9) and four studies (4/6) that included patients with CKD [19,23,25,[27][28][29] and ESRD [23][24][25][26] demonstrated that the a-diversity of gut microbiota was significantly lower in patients than in healthy controls, respectively. Three (3/9) and two studies (2/6) that focused on CKD [17,30,31] or ESRD [21,22] suggested that a-diversity was similar in patients and healthy controls, respectively. Tao et al [20] reported that the a-diversity in patients with DN was relatively higher than that in patients with type 2 diabetes mellitus without kidney disease (Table S4).…”

Section: Alpha (A)-diversitymentioning

confidence: 99%

“…Of 17 studies, 13 studies were conducted in China, and four (4/13) studies focused on ESRD. Nine (9/9) studies [17,18,20,[27][28][29][30]32,33] carried in China showed that the b-diversity of gut microbiota in CKD patients was significantly distinct from that of healthy controls; one study [19] carried in Italy revealed that the b-diversity of gut microbiota in IgAN patients was significantly distinct from that of healthy controls, while another study [31] carried in Italy reported an opposite result. Three (3/4) studies [24][25][26] carried in China reported that the b-diversity of gut microbiota in the ESRD patients was significantly distinct from that of healthy controls.…”

Section: Beta (B)-diversitymentioning

confidence: 99%

“…Of 12 studies, 10 studies were conducted in China, and two (2/10) studies focused on ESRD. Five (5/8), two (2/8), and two (2/8) studies demonstrated that Proteobacteria [20,[27][28][29]33], Fusobacteria [18,27], and Bacteroidetes [17,33] were more abundant, while four (4/8) and two (2/8) studies revealed that Firmicutes [17,27,28,33] and Synergistetes [18,29] were less abundant in Chinese CKD patients compared with healthy controls, respectively. However, the two studies conducted in the US [34] and Italy [19] did not identify any taxa with the same alteration in CKD patients.…”

Section: Relatively Distinct Bacterial Taxa At the Phylum Levelmentioning

confidence: 99%

“…In the ESRD subgroup, two (2/4) studies observed that Deltaproteobacteria [22,24], Alphaproteobacteria [23,25], and Bacilli [23,25] were more abundant in ESRD patients than in healthy controls. All the four studies focused on CKD were conducted in China, of which two (2/4) studies observed that Actinobacteria [27,30], Gammaproteobacteria [27,33], and Fusobacteria [17,27] were more abundant while Verrucomicrobiae [27,30] and Betaproteobacteria [27,30] were less abundant in CKD patients than in healthy controls, respectively.…”

Section: Relatively Distinct Bacterial Taxa At the Phylum Levelmentioning

confidence: 99%

See 4 more Smart Citations

Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

et al. 2021

View full text Add to dashboard Cite

Section: Study Selection Characteristics and Qualitymentioning

confidence: 99%

Section: Alpha (A)-diversitymentioning

confidence: 99%

Section: Beta (B)-diversitymentioning

confidence: 99%

Section: Relatively Distinct Bacterial Taxa At the Phylum Levelmentioning

confidence: 99%

Section: Relatively Distinct Bacterial Taxa At the Phylum Levelmentioning

confidence: 99%

See 3 more Smart Citations

Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

et al. 2021

View full text Add to dashboard Cite

Bibliometric analysis of mucosal immunity in IgA nephropathy from 1990 to 2022

Chen,

Yan,

Pan

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

ObjectiveThe study aimed to conduct a bibliometric analysis of mucosal immunity in IgA nephropathy (IgAN) and indicate its current status, hot sopts, and direction of future studies.MethodsThe literature data was collected from the Web of Science Core Collection. CiteSpace 6.1.R3 was employed to conduct a visualization bibliometric analysis of mucosal immunity in IgA nephropathy, including authors, countries, journals, keywords, organizations, references, the bursts of keywords and references, and the timeline of keyword clusters and reference clusters.ResultsA total of 315 publications from 1990 to 2022 were included. The number of articles in this field has increased in recent years. Suzuki H, Coppo R, and Feehally J took the first place parallelly with 18 articles. Japan contributes the most articles, accounting for 27.3% of all the publications. The institutions with the most publications were Juntendo University and University of Alabama Birmingham. 453 keywords were concluded in the analysis, which mainly focus on the mucosal pathogenesis and therapy of the IgAN. The top five co‐cited reference cluster are “aberrantly glycosylated IgA,” “corticosteroids,” “animal models,” “o‐glycosylationm” and “microRNA‐630.” The most recently burst of keyword is “tonsillectomy” and “gut.”ConclusionThis was the first bibliometric analysis to systematically analyze the mucosal immunity in IgAN, which obtained the current status and indicated the future research hotspots and development trends. The gut microbiota and the related therapy‐targeted mucosal immunity might be the future research hotspot.

show abstract

How will artificial intelligence and bioinformatics change our understanding of IgA Nephropathy in the next decade?

2021

View full text Add to dashboard Cite

IgA nephropathy (IgAN) is the most common glomerulonephritis. It is characterized by the deposition of immune complexes containing immunoglobulin A (IgA) in the kidney’s glomeruli, triggering an inflammatory process. In many patients, the disease has a progressive course, eventually leading to end-stage kidney disease. The current understanding of IgAN’s pathophysiology is incomplete, with the involvement of several potential players, including the mucosal immune system, the complement system, and the microbiome. Dissecting this complex pathophysiology requires an integrated analysis across molecular, cellular, and organ scales. Such data can be obtained by employing emerging technologies, including single-cell sequencing, next-generation sequencing, proteomics, and complex imaging approaches. These techniques generate complex “big data,” requiring advanced computational methods for their analyses and interpretation. Here, we introduce such methods, focusing on the broad areas of bioinformatics and artificial intelligence and discuss how they can advance our understanding of IgAN and ultimately improve patient care. The close integration of advanced experimental and computational technologies with medical and clinical expertise is essential to improve our understanding of human diseases. We argue that IgAN is a paradigmatic disease to demonstrate the value of such a multidisciplinary approach.

show abstract

Modifications of gut microbiota are associated with the severity of IgA nephropathy in the Chinese population

Cited by 39 publications

References 27 publications

Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review

Bibliometric analysis of mucosal immunity in IgA nephropathy from 1990 to 2022

How will artificial intelligence and bioinformatics change our understanding of IgA Nephropathy in the next decade?

Contact Info

Product

Resources

About